登录 | 注册 | English
#
用户登录
用 户 名 :
密 码:
找回密码 是否下次登录
用户注册
* 用户名
* 密   码
* 确认密码
* 姓   名
性   别
出生日期
* 邮   箱
* 联系电话
* 公司名称
职位
* 通讯地址
找回密码#
用 户 名 :
邮箱:
首页>技术与应用>月旭论文

Mogrol represents a novel leukemia therapeutic,

发布时间:2016-03-01        内容来源:月旭科技

Introduction

Leukemia is a malignant disease of blood cellforming tissues. Unlike solid tumors, malignant hematological tumors cannot be cured by surgical treatment or radiation therapy. Therefore,chemotherapy is the main strategy for leukemia treatment [1]. However, over time, leukemia cells can show a reduced sensitivity to cytotoxic drugs, leading to multi drug resistance. Furthermore, currently available chemotherapeutics can induce adverse side effects[2]. Thus, it is imperative to identify novel chemotherapeutic agents that treat leukemia while minimizing adverse effects.


Increased knowledge of the molecular mechanisms underlying cancer may provide novel

molecular targets for therapeutic intervention [3]. The ERK cascade is primarily activated by growth factors, and is critical for proliferation and survival [4]. Signal transducer and activator of transcription 3 (STAT3) is another wellknown oncogene that is constitutively activated in many human cancers [5]. Emerging literature suggests that ERK and STAT3 signaling may play a critical role in cancer formation and progression [6, 7]. Furthermore, aberrant activation of the ERK pathway [8, 9] and constitutively active STAT3 is frequently found in leukemia [10, 11]. Thus, targeting STAT3 or ERK with novel, low-toxicity anticancer compounds could be promising for leukemia treatment.

浏览

快赢彩票fonda-gift.com版权所有      Copyright 2013 月旭科技(上海)股份有限公司     Designed by Wanhu

月旭论坛

免责声明: 本站资料及图片来源互联网文章,本网不承担任何由内容信息所引起的争议和法律责任。所有作品版权归原创作者所有,与本站立场无关,如用户分享不慎侵犯了您的权益,请联系我们告知,我们将做删除处理!